Watch Our Video and then Read the Annoucement Below
Two-Year Invasive Lobular Carcinoma Research Fellowship Is the First Lobular Breast Cancer-Focused Research Fellowship Solicitation for Both Organizations
The Lobular Breast Cancer Alliance (LBCA), in conjunction with the American Association for Cancer Research (AACR), is pleased to announce the opening of solicitations for its new 2021 AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship. AACR and LBCA will award a two-year invasive lobular carcinoma (ILC) research fellowship grant later this year in the amount of $120,000 to the most successful applicant. The deadline for letters of intent is July 6, 2021. The fellowship is a joint effort by the two organizations to support and encourage innovative research projects with direct applicability and relevance to ILC and to help establish a successful career path in the field.
“We are grateful to AACR for helping us make this ILC-focused fellowship grant a reality by providing expertise in the grant review, award, and post-award processes,” said Lobular Breast Cancer Alliance Executive Director Laurie Hutcheson.“Being able to fund ILC research directly for the first time this month is an important and historic achievement for LBCA. It has been challenging for scientists to study ILC because it has been harder to find subjects, cell lines, and to obtain funding. We are thrilled that we can directly contribute to advancing knowledge of ILC, and we are eager to see the new research that these grants will stimulate.”
“We are delighted to offer this important research grant opportunity targeting invasive lobular carcinoma alongside the Lobular Breast Cancer Alliance,” says Mitch Stoller, Chief Philanthropic Officer of the AACR Foundation. “AACR thanks the LBCA for its partnership and support of such a grant. We look forward to the program’s launch and the scientific discovery that follows selection of the most meritorious research in the field.”
Otto Metzger, MD, chair of the Lobular Breast Cancer Alliance Scientific Advisory Board and a clinician-trialist with a special interest in ILC at Dana-Farber Cancer Institute said, “We know ILC is harder to detect than the more common invasive ductal carcinoma, and it sometimes recurs in different parts of the body. But we need to learn more about the different characteristics of ILC and what this could mean for treatment. This fellowship will allow us to better fulfill a core part of LBCA’s mission to advance research to identify the best methods for diagnosing and treating ILC. I look forward to see what new science emerges from the successful applicant’s ILC research.”
The first stage of the ILC research fellowship application process is the submission of a competitive letter of intent. Successful candidates will be invited to submit full applications. Those interested can learn more at https://www.aacr.org/grants/aacr-lobular-breast-cancer-alliance-invasive-lobular-carcinoma-research-fellowship/.
###
About Lobular Breast Cancer Alliance
Founded in 2017 by patient advocates with ILC, the Lobular Breast Cancer Alliance engages patients, clinicians, and researchers to increase knowledge of lobular breast disease and promote lobular breast cancer research. Working with the guidance of an international, expert scientific advisory board of breast cancer researchers and clinicians, patient advocate volunteers, and through growing collaborations with other breast cancer advocacy organizations, Lobular Breast Cancer Alliance provides a platform for ILC research, maintains a library of current lobular breast cancer studies, and identifies clinical trials and ILC patient research advocacy opportunities with a focus on lobular breast disease. Visit us at lobularbreastcancer.org.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes 48,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 127 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops—the largest of which is the AACR Annual Meeting, with more than 74,000 attendees for the 2020 virtual meetings and more than 22,500 attendees for past in-person meetings. In addition, the AACR publishes nine prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.
